Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Research

Targeted Screening for Chronic Q Fever, the Netherlands

Daphne F.M. ReukersComments to Author , Pieter T. de Boer, Alfons O. Loohuis, Peter C. Wever, Chantal P. Bleeker-Rovers, Arianne B. van Gageldonk-Lafeber, Wim van der Hoek, and Aura Timen
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.F.M. Reukers, P.T. de Boer, A.B. van Gageldonk-Lafeber, W. van der Hoek, A. Timen); Q-Support Foundation, ’s-Hertogenbosch, the Netherlands (A.O. Loohuis); Radboud University Medical Center, Nijmegen, the Netherlands (A.O. Loohuis, C.P. Bleeker-Rovers); Jeroen Bosch Hospital, ’s-Hertogenbosch (P.C. Wever); Vrije Universiteit, Amsterdam (A. Timen)

Main Article

Table 1

ICPC codes used for the selection of patients to be invited for participation in the chronic Q fever screening program, the Netherlands*

ICPC code Description
K99.01 Aortic aneurysm
K83 Nonrheumatic valve disease
K73 Congenital malformation(s) of the cardiovascular system
K71 Acute rheumatism/rheumatic heart disease
B73 Leukemia
B74 Other malignancy of the blood/lymphatic system
B90 HIV infection
D94 Ulcerative colitis/chronic enteritis (regionalis)
L04A Use immunosuppressants (excluding corticosteroids) in the past 12 months

*ICPC, International Classification of Primary Care.

Main Article

Page created: May 06, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external